ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at SLEEP 2024 , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX.
- PLEASANTON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have been accepted for presentation at SLEEP 2024 , a joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, June 1-5 in Houston, TX.
- Data from 91 patients with OSA found that 98% of patients with mild and moderate OSA were successfully treated to an AHI
- These results indicate that ProSomnus precision OAT devices are associated with high levels of satisfaction among patients and providers.
- “ProSomnus is proud to be associated with these scientific abstracts which further investigate and establish the clinical safety and performance of precision oral appliance therapy for patients with Obstructive Sleep Apnea.”